[go: up one dir, main page]

NO2764099T3 - - Google Patents

Info

Publication number
NO2764099T3
NO2764099T3 NO12838648A NO12838648A NO2764099T3 NO 2764099 T3 NO2764099 T3 NO 2764099T3 NO 12838648 A NO12838648 A NO 12838648A NO 12838648 A NO12838648 A NO 12838648A NO 2764099 T3 NO2764099 T3 NO 2764099T3
Authority
NO
Norway
Application number
NO12838648A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2764099T3 publication Critical patent/NO2764099T3/no

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/90Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NO12838648A 2011-10-04 2012-10-04 NO2764099T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Publications (1)

Publication Number Publication Date
NO2764099T3 true NO2764099T3 (no) 2018-04-21

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12838648A NO2764099T3 (no) 2011-10-04 2012-10-04

Country Status (14)

Country Link
US (7) US20140228246A1 (no)
EP (1) EP2764099B1 (no)
JP (2) JP6147259B2 (no)
AU (1) AU2012320088C1 (no)
CA (1) CA2850274A1 (no)
CY (1) CY1120087T1 (no)
DK (1) DK2764099T3 (no)
ES (1) ES2660975T3 (no)
HU (1) HUE036537T2 (no)
NO (1) NO2764099T3 (no)
PT (1) PT2764099T (no)
SG (1) SG11201401183UA (no)
TR (1) TR201802420T4 (no)
WO (1) WO2013050962A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004470B1 (en) 2013-05-31 2018-03-14 Eaton Corporation Hydraulic system and method for reducing boom bounce with counter-balance protection
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
US10745667B2 (en) 2015-03-23 2020-08-18 Yao Tang Methods of primary tissue culture and drug screening using autologous serum and fluids
US20180089363A1 (en) * 2015-04-22 2018-03-29 Ono Pharmaceutical Co., Ltd. Method for extracting lead compound, method for selecting drug discovery target, device for creating scatter diagram, and data visualization method and visualization device
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
CA2999054A1 (en) * 2015-10-20 2017-04-27 Celcuity Llc Methods of preparing a primary cell sample
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) * 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
US20190361006A1 (en) * 2017-02-08 2019-11-28 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
BR112019020953A2 (pt) 2017-04-05 2020-05-05 Yeda Res & Dev sistema de cultura ex-vivo e métodos de uso do mesmo
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) * 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172592A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from a ratio of expression levels of two sets of genes
WO2020191105A2 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
IL309061A (en) 2021-06-06 2024-02-01 Yeda res & development co ltd Combined treatment for cancer
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression
US12312631B1 (en) 2022-06-15 2025-05-27 SageMedic Corporation High-throughput multiplexed sensitivity and resistance assay
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
WO2008060377A2 (en) * 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
WO2010120329A1 (en) * 2009-04-15 2010-10-21 The University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
JPWO2011148669A1 (ja) * 2010-05-25 2013-07-25 株式会社島津製作所 大腸がんマーカービトロネクチン、及び採血試料中のビトロネクチン濃度の分析方法

Also Published As

Publication number Publication date
ES2660975T3 (es) 2018-03-26
US20140228246A1 (en) 2014-08-14
JP2014534809A (ja) 2014-12-25
EP2764099A4 (en) 2015-05-06
WO2013050962A1 (en) 2013-04-11
US20190383795A1 (en) 2019-12-19
EP2764099A1 (en) 2014-08-13
US20190346428A1 (en) 2019-11-14
US20190170730A1 (en) 2019-06-06
JP6378273B2 (ja) 2018-08-22
AU2012320088B9 (en) 2015-07-16
CA2850274A1 (en) 2013-04-11
HUE036537T2 (hu) 2018-07-30
DK2764099T3 (en) 2018-02-26
AU2012320088B2 (en) 2015-07-02
US20200064333A1 (en) 2020-02-27
US20190353640A1 (en) 2019-11-21
JP2017061448A (ja) 2017-03-30
CY1120087T1 (el) 2018-12-12
AU2012320088A1 (en) 2014-05-01
JP6147259B2 (ja) 2017-06-14
TR201802420T4 (tr) 2018-03-21
SG11201401183UA (en) 2014-09-26
US20190383796A1 (en) 2019-12-19
AU2012320088C1 (en) 2016-03-17
PT2764099T (pt) 2018-02-28
EP2764099B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
BR112013022641A2 (no)
BR112013031251A2 (no)
BR112013027245A2 (no)
BR112013024383A2 (no)
BR112013023185A2 (no)
BR112013022995A2 (no)
BR112013026905A2 (no)
BR112013017670A2 (no)
BR112013027830A2 (no)
AP3853A (no)
BR112013026744A2 (no)
BR112013023927A2 (no)
BR112013027452A2 (no)
BR112013024365A2 (no)
BR112013028733A2 (no)
BR112013027121A2 (no)
BR112013024588A2 (no)
BR112013031556A2 (no)
BR112013026790A2 (no)
BR112013032368A2 (no)
NO2764099T3 (no)
BR112013032377A2 (no)
BR112013032380A2 (no)
BR112013027836A2 (no)
BR112013018949A2 (no)